Ozempic vs. Wegovy: Same Drug, Different FDA Approval

Ozempic and Wegovy are the same active ingredient, made by the same manufacturer, and routinely used interchangeably in casual conversation. They are not the same product on the FDA's books. Knowing the difference matters because "semaglutide" is the word compounded providers borrow to imply equivalence with whichever brand you've heard of — and the actual regulatory picture is more specific than that.

Both are semaglutide — but two separate approvals

Ozempic was approved first, in 2017, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; the FDA later expanded its label to include reducing the risk of major adverse cardiovascular events and, more recently, reducing the risk of sustained kidney-function decline in patients with type 2 diabetes and chronic kidney disease¹. Wegovy is a separate FDA approval, granted in 2021, specifically for chronic weight management — to reduce excess body weight and maintain the loss, in combination with a reduced-calorie diet and increased physical activity, in adults with obesity or with overweight plus a weight-related condition². Same drug, different green light.

The dose ceilings are not the same

This is the detail that gets lost in the shorthand: Ozempic's maximum recommended dosage is 2 mg once weekly¹. Wegovy's approved maintenance dose goes higher, to 2.4 mg once weekly — the exact dose tested in the pivotal STEP-1 trial, which produced a mean body-weight change of about −14.9% over 68 weeks³. A patient on Ozempic at its top diabetes dose is not automatically on the dose the weight-management trial evidence is built on. That distinction is exactly why our semaglutide vs. tirzepatide trial breakdown and our WeighScore's dose-and-formulation dimension both weight titration ceiling as a real factor, not a technicality.

Why the labeling difference actually matters to you

Two consequences follow directly from having two separate approvals. First, insurance and formulary logic often treats them differently — a plan may cover Ozempic for a diagnosed diabetes indication while excluding Wegovy for a weight-only indication, an asymmetry we walk through in does insurance cover GLP-1 weight-loss drugs? Second, "off-label" has a precise meaning here: prescribing Ozempic specifically for weight loss in someone without diabetes is off-label use of an on-market drug, which is legal for a licensed prescriber to do but is a different regulatory posture than prescribing Wegovy for the same goal on-label. A provider should be able to tell you, plainly, which posture your prescription sits in.

Where compounded "semaglutide" fits into this picture

Neither Ozempic nor Wegovy is what most compounded telehealth providers actually dispense — those products use compounded semaglutide base or salt forms prepared by a pharmacy, a different regulatory category covered in depth in is compounded semaglutide legit and safe? and in why compounded GLP-1's legality hinges on the FDA shortage list A provider that markets its compounded product as "the same as Ozempic" or "the same as Wegovy" is making a molecule-level claim, not a product-level one — accurate about the active ingredient, imprecise about everything the FDA actually reviewed.

So which name should you be asking for?

Neither, by itself — ask for the indication and the dose. If your goal is glycemic control in diagnosed type 2 diabetes and your prescriber and insurer are working from that diagnosis, Ozempic's approval and formulary pathway fit. If your goal is weight management without a diabetes diagnosis, Wegovy is the on-label product built and tested for exactly that use, at the higher dose the trial evidence supports. If a compounded alternative is on the table for cost or access reasons, understand what changes — see what compounded GLP-1 actually costs per month and weigh it against our six-point provider checklist

The honest bottom line

"It's the same drug" is true and also not the whole answer. Ozempic and Wegovy are the same molecule reviewed by the FDA for two different purposes, at two different dose ceilings, with two different labels — and that difference flows into what your insurance will pay for and what a compounded provider is actually promising when it invokes either brand name. Compare graded providers and their molecule and dosing menus in our reviews and comparisons A licensed clinician should be the one deciding which product and dose fit your diagnosis.